Changeflow GovPing Pharma & Drug Safety Polymer-lipid Nanocomplex for Enhanced Hydropho...
Routine Notice Added Final

Polymer-lipid Nanocomplex for Enhanced Hydrophobic Drug Solubility

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Therapeutics (A61P)
Published March 25th, 2026
Detected April 1st, 2026
Email

Summary

The European Patent Office published patent application EP3941439A1 for the Council for Scientific and Industrial Research covering a polymer-lipid nanocomplex formulation that enhances aqueous solubilisation and absorption of hydrophobic active compounds. The invention addresses drug delivery challenges for poorly soluble pharmaceuticals across multiple therapeutic areas including anti-obesity, anxiolytic, antidepressant, anti-inflammatory, antimicrobial, and antiparasitic applications.

What changed

EPO published patent application EP3941439A1 on March 25, 2026, granting the Council for Scientific and Industrial Research protection for a polymer-lipid nanocomplex technology that improves solubility and absorption of hydrophobic drugs. The designated states cover major European markets including DE, FR, GB, IT, ES, NL, BE, CH, and others. The patent claims formulations using specific lipid components and polymer matrices for drug delivery applications.

Patent publication does not create compliance obligations. Entities developing competing formulations for hydrophobic drug delivery should conduct freedom-to-operate analysis. The 20-year patent term from priority date will provide market exclusivity. No action required unless the entity's R&D involves similar polymer-lipid nanocomplex technologies.

Source document (simplified)

← EPO Patent Bulletin

POLYMER-LIPID NANOCOMPLEX FOR ENHANCED AQUEOUS SOLUBILISATION AND ABSORPTION OF HYDROPHOBIC ACTIVE COMPOUNDS

Publication EP3941439A1 Kind: A1 Mar 25, 2026

Applicants

Council for Scientific and Industrial Research

Inventors

NKUNA, Tshepo Patric, KALOMBO, Michel Lonji

IPC Classifications

A61K 9/107 20060101AFI20201120BHEP A61K 9/51 20060101ALI20201120BHEP A61K 9/19 20060101ALI20201120BHEP A61K 47/02 20060101ALI20201120BHEP A61K 47/08 20060101ALI20201120BHEP A61K 47/10 20170101ALI20201120BHEP A61K 47/12 20060101ALI20201120BHEP A61K 47/26 20060101ALI20201120BHEP A61K 47/32 20060101ALI20201120BHEP A61K 47/34 20170101ALI20201120BHEP A61K 31/05 20060101ALI20201120BHEP A61K 31/137 20060101ALI20201120BHEP A61K 31/496 20060101ALI20201120BHEP A61P 3/04 20060101ALI20201120BHEP A61P 25/22 20060101ALI20201120BHEP A61P 25/24 20060101ALI20201120BHEP A61P 29/00 20060101ALI20201120BHEP A61P 31/06 20060101ALI20201120BHEP A61P 31/10 20060101ALI20201120BHEP A61P 31/12 20060101ALI20201120BHEP A61P 33/06 20060101ALI20201120BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP3941439A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing 5411 Legal Services
Activity scope
Patent Filing Drug Formulation Research Intellectual Property
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Intellectual Property Healthcare

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Therapeutics (A61P) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.